1. Introduction {#sec1-medicina-56-00345}
===============

The Epstein--Barr virus (EBV) is a ubiquitous human herpesvirus associated with several lymphoid and epithelial malignancies, including Burkitt's lymphoma, Hodgkin's lymphoma, nasal NK/T cell lymphoma, and a subset of gastric carcinomas (GCs) \[[@B1-medicina-56-00345],[@B2-medicina-56-00345],[@B3-medicina-56-00345],[@B4-medicina-56-00345],[@B5-medicina-56-00345],[@B6-medicina-56-00345]\]. In 1990, Burke et al. first detected the EBV genomes in a small group of GCs using a polymerase chain reaction \[[@B1-medicina-56-00345]\]. Shibata et al. demonstrated that EBV genomes were uniformly present in GC cells, resembling lymphoepithelioma cells \[[@B4-medicina-56-00345]\]. After that, EBV involvement was detected not only in lymphoepithelioma-like GCs but also in a subset of ordinary GCs \[[@B4-medicina-56-00345],[@B7-medicina-56-00345]\].

EBV-associated gastric cancers (EBVaGCs) have a unique molecular signature, which has defined this group of tumors as a distinctive molecular subtype of gastric cancer that accounts for approximately 10% of all GCs \[[@B2-medicina-56-00345],[@B3-medicina-56-00345],[@B4-medicina-56-00345]\]. Thus, EBVaGC is the most common cancer among EBV-related malignancies. However, the prevalence of EBV infection in GCs has differed by reports and histologic subtypes \[[@B7-medicina-56-00345],[@B8-medicina-56-00345],[@B9-medicina-56-00345],[@B10-medicina-56-00345],[@B11-medicina-56-00345],[@B12-medicina-56-00345],[@B13-medicina-56-00345],[@B14-medicina-56-00345],[@B15-medicina-56-00345],[@B16-medicina-56-00345],[@B17-medicina-56-00345],[@B18-medicina-56-00345],[@B19-medicina-56-00345],[@B20-medicina-56-00345],[@B21-medicina-56-00345],[@B22-medicina-56-00345],[@B23-medicina-56-00345],[@B24-medicina-56-00345],[@B25-medicina-56-00345],[@B26-medicina-56-00345],[@B27-medicina-56-00345],[@B28-medicina-56-00345],[@B29-medicina-56-00345],[@B30-medicina-56-00345],[@B31-medicina-56-00345],[@B32-medicina-56-00345],[@B33-medicina-56-00345],[@B34-medicina-56-00345],[@B35-medicina-56-00345],[@B36-medicina-56-00345],[@B37-medicina-56-00345],[@B38-medicina-56-00345],[@B39-medicina-56-00345],[@B40-medicina-56-00345],[@B41-medicina-56-00345],[@B42-medicina-56-00345],[@B43-medicina-56-00345],[@B44-medicina-56-00345],[@B45-medicina-56-00345],[@B46-medicina-56-00345],[@B47-medicina-56-00345],[@B48-medicina-56-00345],[@B49-medicina-56-00345],[@B50-medicina-56-00345],[@B51-medicina-56-00345],[@B52-medicina-56-00345],[@B53-medicina-56-00345],[@B54-medicina-56-00345],[@B55-medicina-56-00345],[@B56-medicina-56-00345],[@B57-medicina-56-00345],[@B58-medicina-56-00345],[@B59-medicina-56-00345],[@B60-medicina-56-00345],[@B61-medicina-56-00345],[@B62-medicina-56-00345],[@B63-medicina-56-00345],[@B64-medicina-56-00345],[@B65-medicina-56-00345],[@B66-medicina-56-00345],[@B67-medicina-56-00345]\]. Furthermore, cumulative information cannot be obtained from individual studies. As part of The Cancer Genome Atlas (TCGA) project, EBVaGCs are associated with distinct molecular changes, as follows: DNA hypermethylation, high frequency of *PIK3CA* mutation, *JAK2* gene amplification, programmed death-ligand 1/programmed cell death 1 ligand 2 (PD-L1/PD-L2) overexpression, and cyclin-dependent kinase inhibitor 2A (*CDKN2A*) silencing \[[@B2-medicina-56-00345]\]. Recently, the loss of AT-rich interactive domain-containing protein 1A (ARID1A) was found in 20% of GCs and significantly correlated with EBVaGCs, PD-L1 status, as well as microsatellite instability (MSI) \[[@B64-medicina-56-00345]\]. As the incidences and clinical features of GCs differ between regions, the clinicopathological characteristics of EBVaGCs may vary according to the various factors. In the present study, we investigate the clinicopathologic significance of EBVaGCs from eligible studies and perform the subgroup analysis to elucidate the EBV infection rate. We also evaluate the differences in the expression of various markers between EBVaGCs and non-EBVaGCs.

2. Materials and Methods {#sec2-medicina-56-00345}
========================

2.1. Published Study Search and Selection Criteria {#sec2dot1-medicina-56-00345}
--------------------------------------------------

Relevant articles were obtained by searching the PubMed database on 31 January 2020. For the search, the following keywords were used: "gastric carcinoma or gastric cancer or stomach cancer" and "Epstein--Barr virus or EBV". The titles and abstracts of all searched articles were screened for the inclusion and exclusion of each article. Included articles contained information on the correlation between EBV positivity and clinicopathological characteristics in GCs. However, case reports, nonoriginal articles, or those not written in English were excluded from the present study. The PRISMA checklist is shown in [Table S1](#app1-medicina-56-00345){ref-type="app"}.

2.2. Data Extraction {#sec2dot2-medicina-56-00345}
--------------------

Data associated with clinicopathological characteristics based on EBV positivity in GCs were extracted from each of the eligible studies \[[@B7-medicina-56-00345],[@B8-medicina-56-00345],[@B9-medicina-56-00345],[@B10-medicina-56-00345],[@B11-medicina-56-00345],[@B12-medicina-56-00345],[@B13-medicina-56-00345],[@B14-medicina-56-00345],[@B15-medicina-56-00345],[@B16-medicina-56-00345],[@B17-medicina-56-00345],[@B18-medicina-56-00345],[@B19-medicina-56-00345],[@B20-medicina-56-00345],[@B21-medicina-56-00345],[@B22-medicina-56-00345],[@B23-medicina-56-00345],[@B24-medicina-56-00345],[@B25-medicina-56-00345],[@B26-medicina-56-00345],[@B27-medicina-56-00345],[@B28-medicina-56-00345],[@B29-medicina-56-00345],[@B30-medicina-56-00345],[@B31-medicina-56-00345],[@B32-medicina-56-00345],[@B33-medicina-56-00345],[@B34-medicina-56-00345],[@B35-medicina-56-00345],[@B36-medicina-56-00345],[@B37-medicina-56-00345],[@B38-medicina-56-00345],[@B39-medicina-56-00345],[@B40-medicina-56-00345],[@B41-medicina-56-00345],[@B42-medicina-56-00345],[@B43-medicina-56-00345],[@B44-medicina-56-00345],[@B45-medicina-56-00345],[@B46-medicina-56-00345],[@B47-medicina-56-00345],[@B48-medicina-56-00345],[@B49-medicina-56-00345],[@B50-medicina-56-00345],[@B51-medicina-56-00345],[@B52-medicina-56-00345],[@B53-medicina-56-00345],[@B54-medicina-56-00345],[@B55-medicina-56-00345],[@B56-medicina-56-00345],[@B57-medicina-56-00345],[@B58-medicina-56-00345],[@B59-medicina-56-00345],[@B60-medicina-56-00345],[@B61-medicina-56-00345],[@B62-medicina-56-00345],[@B63-medicina-56-00345],[@B64-medicina-56-00345],[@B65-medicina-56-00345],[@B66-medicina-56-00345],[@B67-medicina-56-00345]\]. Two independent authors obtained all the data. The data extracted were the author's information, study location, number of patients analyzed, EBV-positive rates, and clinicopathological characteristics by EBV infection. Additional information on immunohistochemical stains is shown in [Table S2](#app1-medicina-56-00345){ref-type="app"}.

2.3. Statistical Analyses {#sec2dot3-medicina-56-00345}
-------------------------

The meta-analysis was performed using the Comprehensive Meta-Analysis software package 2.0 (Biostat, Englewood, NJ, USA). The EBV positivity rate was investigated in GCs. In addition, a subgroup analysis based on study location and histologic subtypes of GCs was performed. The correlations between EBV infection and clinicopathological characteristics were evaluated in GCs. In the present study, the following were included in the evaluated clinicopathological characteristics: age, sex, tumor size, tumor differentiation, histologic type, lymphatic, vascular, and perineural invasions, lymph node metastasis, and pTNM stages. Furthermore, the correlations between EBV positivity and p53, ARID1A, human epidermal growth factor receptor (HER2), and PD-L1 expressions, tumor-infiltrating lymphocytes (TILs), and microsatellite instability (MSI) in GCs were analyzed. We checked the heterogeneity between the studies by Q and *I*^2^ statistics, expressed as *p*-values. Additionally, we conducted a sensitivity analysis to assess the heterogeneity of the eligible studies and the impact of each study on the combined effects. In the meta-analysis, as the eligible studies used various populations, a random-effect model (rather than a fixed-effect model) was determined to be more suitable. The statistical difference between subgroups was evaluated by a metaregression test. We used Begg's funnel plot and Egger's test to assess the publication bias; if significant publication bias was found, the fail-safe N and trim-fill tests were additionally used to confirm the degree of publication bias. The results were considered statistically significant at *p* \< 0.05.

3. Results {#sec3-medicina-56-00345}
==========

3.1. Selection and Characteristics of the Studies {#sec3dot1-medicina-56-00345}
-------------------------------------------------

In this study, 1301 relevant articles were found from the PubMed database and reviewed for a meta-analysis. Of these, 405 articles had no or a lack of sufficient information for the meta-analysis. A further 346 were excluded due to nonoriginal articles. Among the remaining articles, 489 reports were excluded for the following reasons: nonhuman studies (*n* = 238), articles on other diseases (*n* = 185), in a language other than English (*n* = 40), and duplication (*n* = 26); see [Figure 1](#medicina-56-00345-f001){ref-type="fig"}. Finally, 61 eligible articles were selected and included for the meta-analysis ([Table 1](#medicina-56-00345-t001){ref-type="table"}). These studies included 19,747 GC patients with and without EBV infection (2063 and 17,684, respectively).

3.2. Epstein--Barr virus (EBV) Infected Rates of Gastric Carcinomas (GCs) {#sec3dot2-medicina-56-00345}
-------------------------------------------------------------------------

First, we investigated and analyzed the EBV-positive rates of GCs. The estimated EBV-positive rate was 0.113 (95% CI: 0.088--0.143) in overall GC cases. In the subgroup analysis based on study location, the EBV infected rate was the highest in Asia, compared to that in other regions. The EBV infected rate in the Asia region was 0.138 (95% CI: 0.096--0.194). In other areas, the EBV infected rates were 0.103, 0.080, and 0.042 in America, Europe, and Africa, respectively ([Table 2](#medicina-56-00345-t002){ref-type="table"}).

3.3. Correlations Between Epstein--Barr virus (EBV) Infection and Clinicopathological Characteristics in Gastric Carcinomas (GCs) {#sec3dot3-medicina-56-00345}
---------------------------------------------------------------------------------------------------------------------------------

The clinicopathological characteristics, according to EBV positivity, were investigated in GCs. The male patients showed a significantly higher estimation rate in the EBV-positive group than in the EBV-negative group (0.824 vs. 0.639; *p* \< 0.001 in a metaregression test). Other clinicopathological characteristics, including age, tumor size, tumor differentiation, lymphatic, vascular, and perineural invasions, pT stage, lymph node metastasis, and pTNM stage, had no significant differences between EBV-infected and noninfected GCs ([Table 3](#medicina-56-00345-t003){ref-type="table"}). Next, the EBV-positive rates by histologic type of GC were investigated ([Table 4](#medicina-56-00345-t004){ref-type="table"}). The EBV-positive rate of GC with lymphoid stroma was 0.573 (95% CI: 0.428--0.706). This GC with lymphoid stroma showed higher EBV-positive rates compared to other tumor subtypes such as tubular adenocarcinoma (0.174), poorly cohesive carcinoma (0.078), papillary carcinoma (0.022), mucinous carcinoma (0.053), and undifferentiated carcinoma (0.111).

PD-L1 expressions in tumor and immune cells were significantly higher in EBVaGCs than in non-EBVaGCs ([Table 5](#medicina-56-00345-t005){ref-type="table"}). In detail, PD-L1 expression rates of tumor cells were 0.573 (95% CI: 0.449--0.688) and 0.183 (95% CI: 0.118--0.272) in EBVaGCs and non-EBVaGCs, respectively. In addition, the PD-L1 expression rates of immune cells were 0.832 (95% CI: 0.630--0.935) and 0.487 (95% CI: 0.357--0.619) in EBVaGCs and non-EBVaGCs, respectively. ARID1A was highly expressed in EBVaGCs compared to non-EBVaGCs (0.29 vs. 0.170; *p* = 0.021 in a metaregression test). HER2 expression was higher in non-EBVaGCs than in EBVaGCs (0.104 vs. 0.048), but with no significant difference in a metaregression test (*p* = 0.051). There was no significant difference in MSI between EBVaGCs and non-EBVaGCs. CD8+ TILs were significantly higher in EBVaGCs than in non-EBVaGCs. In addition, there was no significant correlation between EBV positivity and loss of E-cadherin ([Table S3](#app1-medicina-56-00345){ref-type="app"}).

4. Discussion {#sec4-medicina-56-00345}
=============

In other epithelial malignancies, the prevalence of EBV positivity was found to be 26.37%, 33.44%, and 45.37% in breast, cervical, and oral squamous cell carcinomas, respectively \[[@B68-medicina-56-00345],[@B69-medicina-56-00345],[@B70-medicina-56-00345]\]. The range of EBV positivity reported was variable in GC tissues \[[@B7-medicina-56-00345],[@B8-medicina-56-00345],[@B9-medicina-56-00345],[@B10-medicina-56-00345],[@B11-medicina-56-00345],[@B12-medicina-56-00345],[@B13-medicina-56-00345],[@B14-medicina-56-00345],[@B15-medicina-56-00345],[@B16-medicina-56-00345],[@B17-medicina-56-00345],[@B18-medicina-56-00345],[@B19-medicina-56-00345],[@B20-medicina-56-00345],[@B21-medicina-56-00345],[@B22-medicina-56-00345],[@B23-medicina-56-00345],[@B24-medicina-56-00345],[@B25-medicina-56-00345],[@B26-medicina-56-00345],[@B27-medicina-56-00345],[@B28-medicina-56-00345],[@B29-medicina-56-00345],[@B30-medicina-56-00345],[@B31-medicina-56-00345],[@B32-medicina-56-00345],[@B33-medicina-56-00345],[@B34-medicina-56-00345],[@B35-medicina-56-00345],[@B36-medicina-56-00345],[@B37-medicina-56-00345],[@B38-medicina-56-00345],[@B39-medicina-56-00345],[@B40-medicina-56-00345],[@B41-medicina-56-00345],[@B42-medicina-56-00345],[@B43-medicina-56-00345],[@B44-medicina-56-00345],[@B45-medicina-56-00345],[@B46-medicina-56-00345],[@B47-medicina-56-00345],[@B48-medicina-56-00345],[@B49-medicina-56-00345],[@B50-medicina-56-00345],[@B51-medicina-56-00345],[@B52-medicina-56-00345],[@B53-medicina-56-00345],[@B54-medicina-56-00345],[@B55-medicina-56-00345],[@B56-medicina-56-00345],[@B57-medicina-56-00345],[@B58-medicina-56-00345],[@B59-medicina-56-00345],[@B60-medicina-56-00345],[@B61-medicina-56-00345],[@B62-medicina-56-00345],[@B63-medicina-56-00345],[@B64-medicina-56-00345],[@B65-medicina-56-00345],[@B66-medicina-56-00345],[@B67-medicina-56-00345]\]. However, Chen et al. reported that non-neoplastic gastric tissue did not detect EBV positivity \[[@B71-medicina-56-00345]\]. A TCGA study stated that the incidence of EBVaGCs was 9% \[[@B2-medicina-56-00345]\]. Previous meta-analyses have reported the range as 2--20% and 6--33% \[[@B72-medicina-56-00345],[@B73-medicina-56-00345]\]. In addition, the clinicopathological features of EBV positivity in GCs were variable, according to reports \[[@B72-medicina-56-00345],[@B73-medicina-56-00345]\]. Therefore, the impact of variable EBV positivity on the controversy of clinicopathological implications of EBV in GCs needs to be elucidated. The present study includes a detailed meta-analysis of the clinicopathological implications of EBV positivity in GCs.

In the present study, the estimated EBV positive rate was 11.3%. EBV positive rates ranged from 1.2% to 89.2% in the individual eligible studies \[[@B7-medicina-56-00345],[@B8-medicina-56-00345],[@B9-medicina-56-00345],[@B10-medicina-56-00345],[@B11-medicina-56-00345],[@B12-medicina-56-00345],[@B13-medicina-56-00345],[@B14-medicina-56-00345],[@B15-medicina-56-00345],[@B16-medicina-56-00345],[@B17-medicina-56-00345],[@B18-medicina-56-00345],[@B19-medicina-56-00345],[@B20-medicina-56-00345],[@B21-medicina-56-00345],[@B22-medicina-56-00345],[@B23-medicina-56-00345],[@B24-medicina-56-00345],[@B25-medicina-56-00345],[@B26-medicina-56-00345],[@B27-medicina-56-00345],[@B28-medicina-56-00345],[@B29-medicina-56-00345],[@B30-medicina-56-00345],[@B31-medicina-56-00345],[@B32-medicina-56-00345],[@B33-medicina-56-00345],[@B34-medicina-56-00345],[@B35-medicina-56-00345],[@B36-medicina-56-00345],[@B37-medicina-56-00345],[@B38-medicina-56-00345],[@B39-medicina-56-00345],[@B40-medicina-56-00345],[@B41-medicina-56-00345],[@B42-medicina-56-00345],[@B43-medicina-56-00345],[@B44-medicina-56-00345],[@B45-medicina-56-00345],[@B46-medicina-56-00345],[@B47-medicina-56-00345],[@B48-medicina-56-00345],[@B49-medicina-56-00345],[@B50-medicina-56-00345],[@B51-medicina-56-00345],[@B52-medicina-56-00345],[@B53-medicina-56-00345],[@B54-medicina-56-00345],[@B55-medicina-56-00345],[@B56-medicina-56-00345],[@B57-medicina-56-00345],[@B58-medicina-56-00345],[@B59-medicina-56-00345],[@B60-medicina-56-00345],[@B61-medicina-56-00345],[@B62-medicina-56-00345],[@B63-medicina-56-00345],[@B64-medicina-56-00345],[@B65-medicina-56-00345],[@B66-medicina-56-00345],[@B67-medicina-56-00345]\]. In previous meta-analyses, EBV positive rates have been reported as 7.5% and 12.6% in 2010 and 2019, respectively \[[@B74-medicina-56-00345],[@B75-medicina-56-00345]\]. Various factors, including the eligible studies, may have affected the differences of EBV positivity between meta-analyses. In Murphy's report, a subgroup analysis based on study location was performed, and the estimated EBV positive rates in America, Asia, and Europe were 9.88%, 8.28%, and 8.70%, respectively \[[@B72-medicina-56-00345]\]. In the current study, the positive rate was highest in Asia at 13.8%. However, there were no significant differences between study locations in the metaregression test. Lee et al. reported that locations with a high prevalence of GCs had low EBV positivity \[[@B76-medicina-56-00345]\]. They showed only odds ratios according to study locations, but not the estimated rates. As the criteria of the odds ratio were not described, interpretation of the odds ratio was not possible. They described that the EBV-positive rate of Asians was 8.4% through simple estimation using the raw data of each study. A meta-analysis did not obtain this result. Moreover, the estimated EBV-positive rates of Caucasian and Hispanic patients did not differ from Asians. In another meta-analysis, there was no significant difference in EBV-positive rates between study locations \[[@B75-medicina-56-00345]\].

In addition, EBV positivity rates can differ according to the histologic type of GC. The highest EBV-positive rate was found in GC with lymphoid stroma at 57.3%. The implications of study location and ethnicity on EBV positivity may be less important when compared to the subtype of GC. Furthermore, the impact of studied years can contribute to varying EBV-positive rates. Additionally, we investigated EBV positivity in tubular adenocarcinoma according to study years. Based on 2017 data, EBV-positive rates were 0.113 (95% CI: 0.063--0.195) and 0.375 (95% CI: 0.132--0.703) after 2017 and before 2017, respectively, with a significant difference between subgroups (*p* = 0.012 in a metaregression test; data not shown). The possible causes are different methodologies and different histologic subtypes of the included cases. The cellular component can affect EBV positivity. In GCs, TILs can show EBV positivity \[[@B71-medicina-56-00345]\]. Of course, the use of a PCR method with microdissection is possible for a more detailed examination; however, this limitation cannot be solved by microdissection due to intratumoral and peritumoral lymphocytes. Although PCR methods are more sensitive than in situ hybridization (ISH) methods, EBV positivity should be elucidated by evaluating cellular fractions, such as in ISH \[[@B71-medicina-56-00345]\]. However, a definitive cause for the difference of EBV positivity by study years could not be found.

In previous studies, EBV positivity has been significantly correlated with some clinicopathological characteristics, sex, and tumor location \[[@B22-medicina-56-00345],[@B26-medicina-56-00345],[@B53-medicina-56-00345]\]. In the present study, there was a significant correlation between EBV positivity and the patient's sex; however, EBV positivity was not correlated with lymphovascular invasion or pTNM stage. The clinicopathological significance of EBV infection is different by reports \[[@B24-medicina-56-00345],[@B25-medicina-56-00345],[@B74-medicina-56-00345],[@B75-medicina-56-00345],[@B76-medicina-56-00345]\]. Huang et al. reported that EBV infection in GCs was correlated with high pTNM stages and lymphatic tumor invasion, as opposed to our results \[[@B24-medicina-56-00345],[@B25-medicina-56-00345]\]. Lee et al. reported that EBV positivity was higher in younger patients than in older patients \[[@B76-medicina-56-00345]\]. Li et al. reported a correlation between EBV positivity and lymph node metastasis \[[@B74-medicina-56-00345]\]. However, other meta-analyses showed no correlation between EBV positivity and lymph node metastasis, in agreement with our result \[[@B75-medicina-56-00345],[@B76-medicina-56-00345]\]. For the evaluation of correlation with lymph node metastasis, Li's meta-analysis and our meta-analysis included 5 and 40 datasets, respectively. Moreover, they analyzed their data using odds ratios, unlike our analysis. These discrepancies could be involved in the difference of results between the meta-analyses.

Although the molecular characteristics of GCs have been studied \[[@B2-medicina-56-00345]\], previous meta-analyses have not dealt with their correlation with various molecular markers \[[@B75-medicina-56-00345]\]. In our results, CD8+ TILs and PD-L1 expressions of the tumor and immune cells were more frequently found in EBVaGCs than in non-EBVaGCs. Abundant TILs are one of the histologic features in GCs with EBV infection \[[@B77-medicina-56-00345],[@B78-medicina-56-00345],[@B79-medicina-56-00345]\]. In the TCGA report, PD-L1 gene amplification was elevated in EBVaGCs \[[@B2-medicina-56-00345]\]. Furthermore, PD-L1 immunohistochemical expression in tumor cells was more frequently found in EBVaGCs than in non-EBVaGCs \[[@B28-medicina-56-00345]\]. However, the impact of TILs in GCs is not yet fully understood. In addition, further evaluation of the tumor-infiltrating and peritumoral lymphocytes will be needed in GC with lymphoid stroma, which was significantly associated with high EBV positivity. In GCLS, EBV-positive tumors had more PI3K/AKT pathway mutations than EBV-negative tumors \[[@B80-medicina-56-00345]\]. In addition, because EBVaGCs are significantly correlated with high TILs, new immunotherapeutic strategies associated with T-cells are challenging for the treatment of advanced EBVaGCs \[[@B81-medicina-56-00345],[@B82-medicina-56-00345]\]. ARID1A expression was higher in EBVaGCs than in non-EBVaGCs. In the previous meta-analysis, correlations between EBV positivity and molecular markers, such as p53 and CpG island methylator phenotype, were found \[[@B76-medicina-56-00345]\].

This study has some limitations. First, a subgroup analysis based on EBV detection methods could not be performed due to the methods used in the eligible studies. Second, the impact of study years on EBV positivity could not be fully investigated based on subtypes of GCs. We evaluated only tubular adenocarcinomas among the various GC subtypes. Third, the eligible studies used different antibodies and evaluation criteria for immunohistochemistry. However, subgroup analysis based on antibody and evaluation criteria could not be performed due to insufficient information.

5. Conclusions {#sec5-medicina-56-00345}
==============

Taken together, our results show that the EBV positivity of GCs is frequently found in male patients and GC with lymphoid stroma. Although EBV positivity was highest in Asians, there was no significant difference between study locations. EBV positivity is significantly correlated with ARID1A and PD-L1 expressions, as well as CD8+ TILs in GCs.

The following are available online at <https://www.mdpi.com/1010-660X/56/7/345/s1>, Table S1 PRISMA Checklist, Table S2 Antibody information and evaluation criteria of immunohistochemical stains in eligible studies, and Table S3 The estimated rates of various markers in gastric carcinoma according to the Epstein-Barr virus positivity.
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medicina-56-00345-t001_Table 1

###### 

Main characteristics of the eligible studies.

  ----------------------------------------------------------------------------------------------------------------------------
  Study            Location      Number of Patients   EBV   Study   Location           Number of Patients   EBV          
  ---------------- ------------- -------------------- ----- ------- ------------------ -------------------- ------ ----- -----
  Ahn 2017         Korea         349                  26    323     Ma 2017            China                571    31    540

  Castaneda 2019   Peru          375                  72    303     Martinez-\         Spain                209    13    196
                                                                    Ciarpaglini 2019                                     

  Birkman 2018     Finland       238                  17    221     Min 2016           Korea                145    124   21

  Böger 2017       Germany       484                  22    462     Nogueira 2017      Portugal             82     9     73

  Bösch 2019       Germany       189                  11    178     Noh 2018           Korea                449    36    413

  Baek 2018        Korea         276                  59    217     Osumi 2019         Japan                898    71    827

  Chapel 2000      France        56                   7     49      Pereira 2018       Brazil               286    30    256

  Cho 2004         Korea         24                   19    5       Ramos 2019         Brazil               178    18    160

  de Lima 2012     Brazil        160                  11    149     Ribeiro 2017       Portugal             179    15    164

  De Rosa 2018     Italy         169                  33    136     Roh 2019           Korea                582    41    541

  de Souza 2014    Brazil        125                  12    113     Saito 2017         Japan                232    96    136

  de Souza 2018    Brazil        302                  62    240     Setia 2019         USA/Korea            486    33    453

  Dong 2016        China         855                  59    796     Shen 2017          China                202    42    160

  Gasenko 2019     Latvia        302                  26    276     Shibata 1993       USA                  187    19    168

  Grogg 2003       USA           110                  7     103     Shinozaki 2009     Japan                111    43    68

  Guo 2019         China         270                  18    252     Sun 2019           China                165    2     163

  Han 2016         Korea         410                  30    380     Trimeche 2009      Tunisia              96     4     92

  Huang 2014       Taiwan        1020                 52    968     Truong 2009        USA                  235    12    223

  Huang 2019       Taiwan        1248                 65    1183    Valentini 2019     Italy                70     2     68

  Irkkan 2017      Turkey        105                  8     97      van Beek 2004      Netherlands          566    41    525

  Kawazoe 2017     Japan         487                  25    462     Vo 2002            USA                  108    11    97

  Kawazoe 2019     Japan         225                  14    211     Wang 2005          China                58     13    45

  Kijima 2003      Japan         420                  28    392     Wu 2017            China                340    17    323

  Kim 2019 (a)     Korea         273                  25    248     Xing 2017          China                967    34    933

  Kim 2019 (b)     USA           43                   6     37      Yanagi 2019        Japan                1067   69    998

  Koriyama 2007    Japan         149                  49    100     Zhang 2017         China                218    64    154

  Kwon 2017        Korea         394                  26    368     Yoon 2019          USA                  107    3     104

  Leung 1999       China\        79                   18    61      Yen 2014           Brunei\              81     25    56
                   (Hong Kong)                                                         Darussalam                        

  Li 2016          China         137                  30    107     Zhang 2019         China                1013   58    955

  Lim 2017         Korea         241                  215   26      Zhou 2019          China                300    28    272

  Ma 2016          USA           44                   7     37                                                           
  ----------------------------------------------------------------------------------------------------------------------------

EBV, Epstein--Barr virus.

medicina-56-00345-t002_Table 2

###### 

The estimated rates of Epstein--Barr virus positivity in gastric carcinoma.

  --------------------------------------------------------------------------------------------------------------------
                      Number\      Fixed Effect\          Heterogeneity Test\   Random Effect\         Egger's Test\
                      of Subsets   (95% CI)               (*p*-Value)           (95% CI)               (*p*-Value)
  ------------------- ------------ ---------------------- --------------------- ---------------------- ---------------
  EBV positive rate   61           0.116 (0.111, 0.121)   \<0.001               0.113 (0.088, 0.143)   0.912

  Asia                34           0.121 (0.115, 0.128)   \<0.001               0.138 (0.096, 0.194)   0.238

  America             13           0.132 (0.118, 0.148)   \<0.001               0.103 (0.077, 0.137)   0.002

  Europe              12           0.083 (0.073, 0.095)   \<0.001               0.080 (0.061, 0.106)   0.558

  Africa              1            0.042 (0.016, 0.106)   1.000                 0.042 (0.016, 0.106)   \-
  --------------------------------------------------------------------------------------------------------------------

CI, confidence interval; EBV, Epstein--Barr virus.

medicina-56-00345-t003_Table 3

###### 

Clinicopathological significance of Epstein--Barr virus positivity in gastric carcinomas.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  Number\      Fixed Effect\             Heterogeneity Test\   Random Effect\            Egger's Test (*p*-Value)   MRT (*p*-Value)
                                  of Subsets   (95% CI)                  (*p*-Value)           (95% CI)                                             
  ------------------------------- ------------ ------------------------- --------------------- ------------------------- -------------------------- -----------------
  Age                                                                                                                                               

  EBV-positive                    20           61.848 (61.115, 62.581)   \<0.001               62.161 (60.126, 64.197)   0.693                      0.568

  EBV-negative                    16           63.532 (63.219, 63.846)   \<0.001               63.519 (60.349, 66.690)   0.788                      

  Male ratio                                                                                                                                        

  EBV-positive                    44           0.823 (0.802, 0.843)      0.063                 0.824 (0.796, 0.849)      0.189                      \<0.001

  EBV-negative                    40           0.638 (0.629, 0.647)      \<0.001               0.639 (0.620, 0.658)      0.945                      

  Size (cm)                                                                                                                                         

  EBV-positive                    12           3.840 (3.666, 4.015)      \<0.001               4.890 (4.223, 5.556)      \<0.001                    0.918

  EBV-negative                    7            4.595 (4.507, 4.683)      \<0.001               4.588 (4.354, 4.823)      0.957                      

  Tumor differentiation, poorly                                                                                                                     

  EBV-positive                    20           0.674 (0.630, 0.716)      0.004                 0.682 (0.611, 0.745)      0.514                      0.112

  EBV-negative                    20           0.608 (0.595, 0.622)      \<0.001               0.597 (0.525, 0.665)      0.761                      

  Lymphatic invasion                                                                                                                                

  EBV-positive                    7            0.487 (0.429, 0.546)      \<0.001               0.476 (0.299, 0.659)      0.843                      0.523

  EBV-negative                    7            0.498 (0.483, 0.513)      \<0.001               0.522 (0.454, 0.588)      0.583                      

  Vascular invasion                                                                                                                                 

  EBV-positive                    7            0.297 (0.249, 0.350)      \<0.001               0.286 (0.189, 0.408)      0.636                      0.890

  EBV-negative                    7            0.276 (0.263, 0.290)      \<0.001               0.297 (0.202, 0.413)      0.875                      

  Perineural invasion                                                                                                                               

  EBV-positive                    8            0.415 (0.350, 0.482)      \<0.001               0.399 (0.213, 0.619)      0.807                      0.094

  EBV-negative                    8            0.517 (0.498, 0.535)      \<0.001               0.521 (0.458, 0.584)      0.875                      

  Low pT stage (pT1/T2)                                                                                                                             

  EBV-positive                    33           0.435 (0.401, 0.471)      \<0.001               0.366 (0.274, 0.469)      0.066                      0.670

  EBV-negative                    31           0.413 (0.402, 0.424)      \<0.001               0.350 (0.283, 0.422)      0.141                      

  Lymph node metastasis                                                                                                                             

  EBV-positive                    40           0.493 (0.461, 0.526)      \<0.001               0.595 (0.496, 0.686)      0.014                      0.127

  EBV-negative                    37           0.593 (0.583, 0.604)      \<0.001               0.655 (0.595, 0.711)      0.064                      

  pTNM stage                                                                                                                                        

  EBV-positive                    25           0.507 (0.469, 0.544)      \<0.001               0.500 (0.419, 0.580)      0.738                      0.236

  EBV-negative                    25           0.451 (0.439, 0.463)      \<0.001               0.460 (0.425, 0.496)      0.411                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; MRT, metaregression test; EBV, Epstein--Barr virus.

medicina-56-00345-t004_Table 4

###### 

The estimated rates of Epstein--Barr virus positivity in gastric carcinomas according to the histologic types.

  -----------------------------------------------------------------------------------------------------------------------------
  Histologic Type              Number\      Fixed Effect\          Heterogeneity Test\   Random Effect\         Egger's Test\
                               of Subsets   (95% CI)               (*p*-Value)           (95% CI)               (*p*-Value)
  ---------------------------- ------------ ---------------------- --------------------- ---------------------- ---------------
  Tubular adenocarcinoma       6            0.152 (0.132, 0.174)   \<0.001               0.174 (0.086, 0.320)   0.531

  Poorly cohesive carcinoma    8            0.102 (0.063, 0.160)   0.038                 0.078 (0.033, 0.173)   0.263

  Mixed carcinoma              4            0.043 (0.016, 0.109)   0.306                 0.039 (0.013, 0.113)   0.054

  Papillary carcinoma          2            0.022 (0.004, 0.101)   0.530                 0.022 (0.004, 0.101)   \-

  Mucinous carcinoma           4            0.053 (0.013, 0.190)   0.688                 0.053 (0.013, 0.190)   0.042

  GCLS                         5            0.576 (0.468, 0.676)   0.203                 0.573 (0.428, 0.706)   0.748

  Solid carcinoma              2            0.130 (0.046, 0.316)   0.828                 0.130 (0.046, 0.316)   \-

  Undifferentiated carcinoma   1            0.111 (0.015, 0.500)   1.000                 0.111 (0.015, 0.500)   \-
  -----------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; GCLS, gastric carcinoma with lymphoid stroma.

medicina-56-00345-t005_Table 5

###### 

The estimated rates of various markers in gastric carcinomas according to the Epstein--Barr virus positivity.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Markers                      Number of Subsets   Fixed Effect\          Heterogeneity Test\   Random Effect\         Egger's Test\   MRT\
                                                   (95% CI)               (*p*-Value)           (95% CI)               (*p*-Value)     (*p*-Value)
  ---------------------------- ------------------- ---------------------- --------------------- ---------------------- --------------- -------------
  PD-L1 in tumor cells                                                                                                                 

  EBV-positive                 14                  0.500 (0.447, 0.554)   \<0.001               0.573 (0.449, 0.688)   0.047           \<0.001

  EBV-negative                 14                  0.337 (0.323, 0.352)   \<0.001               0.183 (0.118, 0.272)   0.008           

  PD-L1 in immune cells                                                                                                                

  EBV-positive                 8                   0.610 (0.531, 0.683)   \<0.001               0.832 (0.630, 0.935)   0.007           0.002

  EBV-negative                 8                   0.572 (0.552, 0.592)   \<0.001               0.487 (0.357, 0.619)   0.081           

  p53 overexpression                                                                                                                   

  EBV-positive                 5                   0.359 (0.256, 0.477)   0.223                 0.194 (0.067, 0.446)   0.023           0.090

  EBV-negative                 4                   0.464 (0.418, 0.511)   \<0.001               0.439 (0.314, 0.572)   0.502           

  ARID1A                                                                                                                               

  EBV-positive                 4                   0.295 (0.206, 0.403)   0.309                 0.295 (0.196, 0.418)   0.519           0.021

  EBV-negative                 4                   0.176 (0.153, 0.201)   0.055                 0.170 (0.134, 0.214)   0.530           

  HER2                                                                                                                                 

  EBV-positive                 8                   0.048 (0.024, 0.093)   0.723                 0.048 (0.024, 0.093)   0.167           0.051

  EBV-negative                 8                   0.101 (0.088, 0.115)   \<0.001               0.104 (0.070, 0.152)   0.739           

  Microsatellite instability                                                                                                           

  EBV-positive                 5                   0.087 (0.040, 0.179)   0.240                 0.077 (0.028, 0.190)   0.230           0.536

  EBV-negative                 5                   0.104 (0.089, 0.121)   \<0.001               0.108 (0.069, 0.166)   0.637           

  CD8+ TILs                                                                                                                            

  EBV-positive                 4                   0.705 (0.584, 0.802)   0.100                 0.761 (0.547, 0.894)   0.163           0.001

  EBV-negative                 4                   0.307 (0.275, 0.341)   \<0.001               0.269 (0.141, 0.450)   0.851           
  --------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; MRT, metaregression test; PD-L1, programmed death-ligand 1; EBV, Epstein--Barr virus; ARID1A, AT-rich interactive domain-containing protein 1A; HER2, human epidermal growth factor receptor 2; TIL, tumor-infiltrating lymphocyte.

[^1]: These authors contributed equally to this study.
